<DOC>
	<DOCNO>NCT02695472</DOCNO>
	<brief_summary>The study consist screen period randomize treatment . Approximately 220 subject meet eligibility screen period randomize initiate 12-week , double-blind treatment NSI-189 80 milligrams/day ( provide 40 milligram twice per day ) , NSI-189 40 milligram day , placebo .</brief_summary>
	<brief_title>Study NSI-189 Major Depressive Disorder</brief_title>
	<detailed_description>The screening period range minimum 14 day maximum 28 day . The Investigators determine subject meet eligibility criterion collect demographic medical data permit full characterization subject . The duration randomization period 12 week . Subjects meet inclusion/exclusion criterion Baseline Visit randomize NSI-189 80 milligrams/day , give 40 milligram twice per day , NSI-189 40 milligrams/day , give day , placebo . The treatment double-blinded .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Subject ability understand purpose , potential benefit risk study provide sign date informed consent , authorize use protect health information accordance national local Subject privacy regulation . 2 . Males females 18 60 year age , inclusive , time informed consent . 3 . Diagnosis major depressive disorder , recurrent , per Diagnostic Statistical Manual Mental Disorders , 5th edition criterion confirm Structured Clinical Interview Diagnostic Statistical Manual specific Clinical Trials . Their major depressive episode must least 8 week duration confirm via Structured Clinical Interview Diagnostic Statistical Manual mood module interview administer remote , independent raters , prior baseline visit . 4 . MontgomeryAsberg Depression Scale ( MADRS ) score 20 great , Screening Baseline ( MADRS score confirm 20 great via remote SAFER interview independent rater prior baseline visit ) . 5 . The following applies female Subjects : Nonpregnant , nonlactating female childbearing potential eligible long agree use double barrier method birth control Screening 3 month follow discontinuation IP . Women childbearing potential ( bilateral oophorectomy , bilateral tubal ligation , hysterectomy , postmenopausal least 1 year ) require parameter order eligible . 6 . The following applies male subject : Male subject female partner childbearing potential require use double barrier method birth control practice abstinence study 3 month follow discontinuation Investigational Product . Note : These requirement also apply male subject vasectomy . 7 . Body mass index ( BMI ) ≥19.5 ≤38.0 kg/m2 , Screening . Bodyweight must &gt; 50 kg . 8 . Of stable medical health , opinion Site Investigator , determine Investigator discretion ( medical history , physical examination , vital sign , ECG , clinical laboratory assessment ) . 1 . Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , major disease determine Investigator designee participation study would place subject increase risk serious adverse event . 2 . History cancer malignancy within last 5 year . Note : Subjects basal squamous cell carcinoma may permit study case case basis . 3 . History seizure ; head trauma ; clinically significant find neurologic examination participation study would place subject increase risk serious adverse event . 4 . Previous current diagnosis bipolar schizoaffective disorder psychotic disorder , psychotic symptom current major depressive episode ( accord Diagnostic Statistical Manual Mental Disorders , 5th edition ) . 5 . Subjects concurrent primary psychiatric diagnosis , diagnose Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders , 5th edition , depression . 6 . Subjects delirium , dementia , Parkinson 's disease , Huntington 's disease . 7 . Subjects fail respond two antidepressant trial adequate dose ( define Massachusetts General Hospital Antidepressant Treatment Response ) duration ( least 8 week duration ) current major depressive episode determine local rater confirm independent , remote rater prior baseline visit . 8 . Subjects clinically significant suicidal ideation and/or behavior currently determine Site Investigator , participation study would place subject increase risk serious adverse event . 9 . Subjects current homicidal ideation . 10 . Clinically significant abnormal clinical chemistry value , determine Site Investigator , value Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , total bilirubin creatinine 1.5 time upper limit normal ( ULN ) deem clinically significant Site Investigator ; clinically significant value determine Site Investigator platelet hemoglobin low limit normal ( LLN ) ; normal range value white blood cell ( WBC ) deem clinically significant Site Investigator . 11 . Clinically significant ( determined Investigator ) 12lead Electrocardiogram ( ECG ) abnormality , include correct QT interval use Bazett 's correction method &gt; 450 msec male &gt; 470 msec female . 12 . Subjects ( current ) severe PostTraumatic Stress Disorder ( PTSD ) , severe Obsessive Compulsive Disorder ( OCD ) , severe binge eat disorder , subject anorexia bulimia nervosa active within past three year . 13 . Subjects plan undergo elective invasive procedures/surgeries time study Endofstudy . 14 . Subjects take excluded medication ( See Appendix 1 ) .. 15 . History alcohol drugdependence abuse Diagnostic Statistical Manual Mental Disorders , 5th edition criterion confirm Structured Clinical Interview Diagnostic Statistical Manual specific Clinical Trials within 12 month prior Screening . 16 . Positive screen test baseline test drugsofabuse ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , phencyclidine ) . Note positive test result ( ) benzodiazepine ( ) , opiates , psychostimulants accompany confirmation prescription valid medical reason allow . 17 . Positive serum βhuman chorionic gonadotropin ( βHCG ) test Screening positive urine pregnancy test baseline consistent pregnancy ( female ) . 18 . Donation loss whole blood &gt; 200 mL within 30 day prior dose ≥500 mL within 56 day prior dose . Note : Blood take routine medical evaluation total less 50 mL permit . 19 . Females pregnant , lactating , plan become pregnant study . 20 . Does tolerate venipuncture . 21 . Subjects electroconvulsive therapy within 6 month prior Screening . 22 . Current enrollment drug , biologic , device , clinical study , treatment Investigational Product approve therapy investigational use within 45 day ( 5 halflives , whichever long ) prior Day 1 Investigational Product administration . 23 . Any concurrent disease condition , opinion Investigator , would make subject unsuitable participation clinical study . 24 . Subject , opinion Site Investigator , unable understand protocol requirement , instruction studyrelated restriction , nature , scope possible consequence clinical study . 25 . Subject , opinion Site Investigator , unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup improbability complete clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder ( MDD )</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Neurogenesis</keyword>
	<keyword>Synaptogenesis</keyword>
	<keyword>NSI-189</keyword>
	<keyword>Neuralstem</keyword>
</DOC>